Get this report today!
Table of Contents
Angioedema – Pipeline Review, H1 2012
Global Markets Direct’s, 'Angioedema - Pipeline Review, H1 2012', provides an overview of the Angioedema therapeutic pipeline. This report provides information on the therapeutic development for Angioedema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angioedema. 'Angioedema - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Angioedema.
- A review of the Angioedema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Angioedema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Angioedema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Angioedema pipeline depth and focus of Angioedema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Talk to Alison
00 1 718 618 48 97
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...
Actonel (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Actonel (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
REPORT SCOPE INTRODUCTION REASONS FOR DOING THE STUDY The spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains and antibiotic-resistant organisms have put healthcare ...
... A diagnosed mental health condition as per the icd-10 categories (children do not require a mental health diagnosis, however, must be demonstrating symptoms that indicate they are at significant risk ...
... High stress level 9 quiz: which country 54% Of men and 21% of women have body mass index above 25 46% of population are smokers 35% has high blood pressure 16% has obesity 60 ...
Reportlinker.com © Copyright 2013. All rights reserved.